Good evening, this is Markets Desk with your end-of-day briefing.
Roche Holdings moved sharply on positive Phase three trial data today, as its KRAS inhibitor Divarasib cleared the primary endpoint in the Krascendo one lung cancer study, outperforming rival therapies sotorasib and adagrasib. For Roche, this is a meaningful pipeline win in a competitive oncology space, and investors took notice.
Staying in biotech, sixty Degrees Pharmaceuticals got a quieter but still significant green light, as an independent safety monitoring board cleared its Phase two Babesiosis study to continue after reviewing data from the first six patients. For a small-cap name like SXTP, clean safety data at this stage removes a meaningful overhang and keeps the program alive.
Shifting to markets and the IPO landscape, SpaceX shares are now down twenty-two percent from their post-IPO peak, fitting a pattern seen across major high-profile listings. History suggests these pullbacks tend to find a floor before a more sustained recovery sets in, though timing that inflection remains the central question for growth-oriented investors watching the name closely.
That's the tape. Markets Desk, signing off the floor.
